Revenio Group Corporation (REG1V) - Total Assets
Based on the latest financial reports, Revenio Group Corporation (REG1V) holds total assets worth €135.20 Million EUR (≈ $158.06 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See REG1V net assets for net asset value and shareholders' equity analysis.
Revenio Group Corporation - Total Assets Trend (2000–2024)
This chart illustrates how Revenio Group Corporation's total assets have evolved over time, based on quarterly financial data.
Revenio Group Corporation - Asset Composition Analysis
Current Asset Composition (December 2024)
Revenio Group Corporation's total assets of €135.20 Million consist of 33.3% current assets and 66.8% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 14.6% |
| Accounts Receivable | €14.43 Million | 10.2% |
| Inventory | €10.10 Million | 7.2% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €22.00 Million | 15.6% |
| Goodwill | €63.33 Million | 44.8% |
Asset Composition Trend (2000–2024)
This chart illustrates how Revenio Group Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Revenio Group Corporation worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Revenio Group Corporation's current assets represent 33.3% of total assets in 2024, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 14.6% of total assets in 2024, up from 10.5% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 59.0% of total assets, an increase from 4.0% in 2000.
- Asset Diversification: The largest asset category is goodwill at 44.8% of total assets.
Revenio Group Corporation Competitors by Total Assets
Key competitors of Revenio Group Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Envoy Medical Inc.
NASDAQ:COCH
|
USA | $8.18 Million |
|
Heart Test Laboratories Inc. Common Stock
NASDAQ:HSCS
|
USA | $6.00 Million |
|
NAYA Biosciences, Inc
NASDAQ:NAYA
|
USA | $46.45 Million |
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
Medacta Group SA
SW:MOVE
|
Switzerland | CHF860.76 Million |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥5.03 Billion |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
|
China | CN¥3.71 Billion |
|
Tellgen Corp
SHE:300642
|
China | CN¥2.01 Billion |
Revenio Group Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.12 | 2.16 | 2.71 |
| Quick Ratio | 1.61 | 1.63 | 2.34 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €21.20 Million | €22.60 Million | €22.90 Million |
Revenio Group Corporation - Advanced Valuation Insights
This section examines the relationship between Revenio Group Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.27 |
| Latest Market Cap to Assets Ratio | 3.09 |
| Asset Growth Rate (YoY) | 2.9% |
| Total Assets | €141.34 Million |
| Market Capitalization | $437.29 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Revenio Group Corporation's assets at a significant premium (3.09x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Revenio Group Corporation's assets grew by 2.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Revenio Group Corporation (2000–2024)
The table below shows the annual total assets of Revenio Group Corporation from 2000 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €141.34 Million ≈ $165.24 Million |
+2.86% |
| 2023-12-31 | €137.41 Million ≈ $160.65 Million |
+0.97% |
| 2022-12-31 | €136.09 Million ≈ $159.10 Million |
+9.24% |
| 2021-12-31 | €124.58 Million ≈ $145.65 Million |
+8.88% |
| 2020-12-31 | €114.42 Million ≈ $133.77 Million |
+4.22% |
| 2019-12-31 | €109.79 Million ≈ $128.36 Million |
+396.95% |
| 2018-12-31 | €22.09 Million ≈ $25.83 Million |
+16.02% |
| 2017-12-31 | €19.04 Million ≈ $22.26 Million |
+0.36% |
| 2016-12-31 | €18.98 Million ≈ $22.18 Million |
+2.99% |
| 2015-12-31 | €18.43 Million ≈ $21.54 Million |
-4.71% |
| 2014-12-31 | €19.34 Million ≈ $22.61 Million |
-14.58% |
| 2013-12-31 | €22.64 Million ≈ $26.46 Million |
-9.47% |
| 2012-12-31 | €25.00 Million ≈ $29.23 Million |
+0.99% |
| 2011-12-31 | €24.76 Million ≈ $28.94 Million |
+1.11% |
| 2010-12-31 | €24.48 Million ≈ $28.63 Million |
-7.84% |
| 2009-12-31 | €26.57 Million ≈ $31.06 Million |
-8.19% |
| 2008-12-31 | €28.94 Million ≈ $33.83 Million |
-28.75% |
| 2007-12-31 | €40.62 Million ≈ $47.48 Million |
+135.84% |
| 2006-12-31 | €17.22 Million ≈ $20.13 Million |
+60.04% |
| 2005-12-31 | €10.76 Million ≈ $12.58 Million |
+90.88% |
| 2004-12-31 | €5.64 Million ≈ $6.59 Million |
-13.54% |
| 2003-12-31 | €6.52 Million ≈ $7.62 Million |
-45.33% |
| 2002-12-31 | €11.93 Million ≈ $13.94 Million |
-51.89% |
| 2001-12-31 | €24.79 Million ≈ $28.98 Million |
-37.45% |
| 2001-09-30 | €39.63 Million ≈ $46.34 Million |
-11.46% |
| 2000-12-31 | €44.76 Million ≈ $52.33 Million |
-- |
About Revenio Group Corporation
Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. The company offers iCare IC100, ST500, and IC200 tonometers; iCare HOME2, a tonometer to measure eye pressure; iCare Probes that are accessories of iCare tonometer for measuring intraocular pre… Read more